表紙
市場調査レポート

HAL Allergy BVの製品パイプライン分析

HAL Allergy BV - Product Pipeline Review - 2015

発行 Global Markets Direct 商品コード 321989
出版日 ページ情報 英文 22 Pages
即納可能
価格
本日の銀行送金レート: 1USD=101.50円で換算しております。
Back to Top
HAL Allergy BVの製品パイプライン分析 HAL Allergy BV - Product Pipeline Review - 2015
出版日: 2015年09月30日 ページ情報: 英文 22 Pages
概要

HAL Allergy BVはオランダに本社を置く企業で、アレルギーワクチンの分野では欧州随一の企業です。ハウスダスト、花粉、動植物、虫、カビ、食物など様々なアレルゲンの診断薬やアレルギーワクチンの開発、製造、販売を行っています。同社の製品パイプラインのうち、Purethal、Venomenhal、Sublivacは重度の呼吸器疾患の治療薬として開発が進められています。

当レポートでは、HAL Allergy BVにおける治療薬開発パイプラインの現況と各開発段階の比較分析、薬剤標的、作用機序、投与経路、分子タイプ別の治療薬の評価、最新の企業ニュースや発表、後期段階および中止されたプロジェクトに関する情報などを提供しています。

目次

HAL Allergy BVの基本情報

  • HAL Allergy BVの概要
  • 主要情報
  • 企業情報

HAL Allergy BV:R&Dの概要

  • 主な治療範囲

HAL Allergy BV:パイプラインのレビュー

  • 開発段階別のパイプライン製品
  • 単剤製品

HAL Allergy BV:パイプライン製品の概況

  • 後期段階にあるパイプライン製品
    • 第3相の製品/併用療法モダリティ
  • 臨床段階にあるパイプライン製品
    • 第2相の製品/併用療法モダリティ
    • 第1相の製品/併用療法モダリティ

HAL Allergy BV:薬剤プロファイル

  • Allergen for Birch Pollen Induced Allergic Rhinitis and Rhinoconjunctivitis
  • Allergen for House Dust Mites Induced Allergic Rhinitis and Rhinoconjunctivitis
  • Allergen for Pollen Grass Allergy Induced Allergic Rhinitis and Rhinoconjunctivitis
  • Allergen for Peanut Allergy

HAL Allergy BV:パイプライン分析

  • 投与経路別
  • 分子タイプ別

HAL Allergy BV:本社と子会社の所在地

  • 本社
  • 支社および子会社

付録

図表一覧

このページに掲載されている内容は最新版と異なる場合があります。詳細はお問い合わせください。

目次
Product Code: GMDHC07624CDB

Summary

Global Markets Direct's, 'HAL Allergy BV - Product Pipeline Review - 2015', provides an overview of the HAL Allergy BV's pharmaceutical research and development focus.

This report provides comprehensive information on the current therapeutic developmental pipeline of HAL Allergy BV's, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews latest updates, and featured news and press releases, along with special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

  • The report provides brief overview of HAL Allergy BV including business description, key information and facts, and its locations and subsidiaries
  • The report reviews current pipeline of HAL Allergy BV's human therapeutic division and enlists all their major and minor projects
  • The report features product description and descriptive mechanism of action for key pipeline products along with the product's developmental history and major milestones
  • Special feature on out-licensed and partnered product portfolio
  • The report summarizes all the dormant and discontinued pipeline projects
  • Latest company statement
  • Latest news and deals relating to the HAL Allergy BV's pipeline products

Reasons to buy

  • Evaluate HAL Allergy BV's strategic position with total access to detailed information on its product pipeline
  • Assess the growth potential of HAL Allergy BV in its therapy areas of focus
  • Identify new drug targets and therapeutic classes in the HAL Allergy BV's R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas
  • Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps
  • Develop strategic initiatives by understanding the focus areas of HAL Allergy BV and exploit collaboration and partnership opportunities
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Plan mergers and acquisitions effectively by identifying the most promising pipeline of HAL Allergy BV
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Explore the dormant and discontinued projects of HAL Allergy BV and identify potential opportunities in those areas
  • Avoid Intellectual Property Rights related issues

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • HAL Allergy BV Snapshot
    • HAL Allergy BV Overview
    • Key Information
    • Key Facts
  • HAL Allergy BV - Research and Development Overview
    • Key Therapeutic Areas
  • HAL Allergy BV - Pipeline Review
    • Pipeline Products by Stage of Development
    • Pipeline Products - Monotherapy
  • HAL Allergy BV - Pipeline Products Glance
    • HAL Allergy BV - Late Stage Pipeline Products
      • Phase III Products/Combination Treatment Modalities
    • HAL Allergy BV - Clinical Stage Pipeline Products
      • Phase II Products/Combination Treatment Modalities
      • Phase I Products/Combination Treatment Modalities
  • HAL Allergy BV - Drug Profiles
    • Allergen for Birch Pollen Induced Allergic Rhinitis and Rhinoconjunctivitis
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Allergen for House Dust Mites Induced Allergic Rhinitis and Rhinoconjunctivitis
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Allergen for Pollen Grass Allergy Induced Allergic Rhinitis and Rhinoconjunctivitis
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Allergen for Peanut Allergy
      • Product Description
      • Mechanism of Action
      • R&D Progress
  • HAL Allergy BV - Pipeline Analysis
  • HAL Allergy BV - Pipeline Products by Route of Administration
  • HAL Allergy BV - Pipeline Products by Molecule Type
  • HAL Allergy BV - Locations And Subsidiaries
    • Head Office
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

List of Tables

  • HAL Allergy BV, Key Information
  • HAL Allergy BV, Key Facts
  • HAL Allergy BV - Pipeline by Indication, 2015
  • HAL Allergy BV - Pipeline by Stage of Development, 2015
  • HAL Allergy BV - Monotherapy Products in Pipeline, 2015
  • HAL Allergy BV - Phase III, 2015
  • HAL Allergy BV - Phase II, 2015
  • HAL Allergy BV - Phase I, 2015
  • HAL Allergy BV - Pipeline by Route of Administration, 2015
  • HAL Allergy BV - Pipeline by Molecule Type, 2015

List of Figures

  • HAL Allergy BV - Pipeline by Top 10 Indication, 2015
  • HAL Allergy BV - Pipeline by Stage of Development, 2015
  • HAL Allergy BV - Monotherapy Products in Pipeline, 2015
  • HAL Allergy BV - Pipeline by Top 10 Route of Administration, 2015
  • HAL Allergy BV - Pipeline by Top 10 Molecule Type, 2015
Back to Top